Verve Therapeutics welcomes Bo Cumbo to its Board of Directors

– USA, MA –  Verve Therapeutics (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease today announced the appointment of Bo Cumbo to its board of directors.

“Bo is a highly experienced industry executive with a well-established track record of leading pharmaceutical and life sciences companies through critical processes in drug development and commercial execution,” said co-founder and CEO, Dr. Sekar Kathiresan. “As we focus on continued execution of our regulatory strategy for VERVE-101, as well as the advancement of our second program targeting ANGPTL3 and novel delivery technology, Bo’s expertise will be invaluable. We’re delighted to welcome Bo to the team, as we work to develop potentially life-changing treatments for the millions of people living with or are at risk of cardiovascular disease.”

About Alexander G. Cumbo

Bo Cumbo brings more than 28 years of pharmaceutical and biotechnology industry experience, including leading the commercial launches of 11 specialty or rare disease drugs. He has served as the president and CEO of AavantiBio, Inc., a gene therapy company, since October 2020. From 2013 to 2020, Mr. Cumbo held positions of increasing responsibility at Sarepta Therapeutics, Inc., ultimately serving as EVP and CCO. Before joining Sarepta in 2013, Mr. Cumbo served as VP of sales, key account management, and treatment educator teams at Vertex Pharmaceuticals. During his time at Vertex, he led the launch of Incivek, one of the most successful drug launches in the history of U.S. pharmaceuticals. Mr. Cumbo served in multiple commercial roles supporting the HIV, HBV, and cardiovascular franchises at Gilead Sciences. He received his bachelor of science in laboratory technology from Auburn University.

“Verve has a tremendous opportunity to change the trajectory of how cardiovascular disease is treated around the world by transforming the chronic care model to single-course therapies,” said Mr. Cumbo. “The team has made significant progress, evidenced by its imminent transition to a clinical-stage company with a first-in-class approach to gene editing for cardiovascular disease. I’m excited to partner with the Verve team and by the opportunity to contribute to their pipeline development and expansion efforts in this incredibly valuable area of drug development.”

About Verve Therapeutics

Verve Therapeutics, Inc. is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver to disrupt blood PCSK9 protein production and thereby durably reduce blood LDL-C levels, to reduce a patient’s risk for cardiovascular disease. VERVE-101 is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.

For more information: https://www.vervetx.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team